Literature DB >> 35241532

Optimization of Culture Conditions for the Generation of Canine CD20-CAR-T Cells for Adoptive Immunotherapy.

Osamu Sakai1, Hiroka Yamamoto1, Masaya Igase1, Takuya Mizuno2.   

Abstract

BACKGROUND/AIM: Chimeric antigen receptor (CAR) T cell therapy targeting CD20 has the potential to become a promising novel treatment for canine B cell lymphoid malignancy. However, the optimal approach for producing potent CAR-T cells with favorable phenotype for dogs remains unknown. In this study, we assessed several culture conditions and their effects on the phenotypic characteristics of CD20-CAR-T cells.
MATERIALS AND METHODS: Canine CAR-T cells were generated by incubating with several mitogens in the presence or absence of Akt inhibitor. Gene transduction efficiency and phenotypic characteristics were determined by flow cytometry.
RESULTS: Comparison of several kinds of mitogens revealed that stimulation with phytohemagglutinin has high transduction efficacy, whereas stimulation with concanavalin A was superior in memory T cell formation. Akt inhibition at the initial stage of CAR-T production tended to enhance transduction efficiency and memory T cell formation.
CONCLUSION: This study provides a significant insight into the understanding of the ex vivo expansion of canine T cells in adoptive immunotherapy. Copyright
© 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Adoptive immunotherapy; CD20; Chimeric antigen receptor T cell; culture condition; dogs

Mesh:

Substances:

Year:  2022        PMID: 35241532      PMCID: PMC8931891          DOI: 10.21873/invivo.12763

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  29 in total

1.  T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors:  Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

2.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Authors:  Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney
Journal:  J Clin Invest       Date:  2016-04-25       Impact factor: 14.808

3.  Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy.

Authors:  Qing Zhang; Jiage Ding; Shishuo Sun; Hongyan Liu; Mengmeng Lu; Xiaohuan Wei; Xiaoge Gao; Xiaokang Zhang; Qiang Fu; Junnian Zheng
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

4.  Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.

Authors:  Stephen J Forman; Xiuli Wang; Ryan Urak; Miriam Walter; Laura Lim; ChingLam W Wong; Lihua E Budde; Sandra Thomas
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

5.  Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium.

Authors:  Andrew R Medvec; Christopher Ecker; Hong Kong; Emily A Winters; Joshua Glover; Angel Varela-Rohena; James L Riley
Journal:  Mol Ther Methods Clin Dev       Date:  2017-11-07       Impact factor: 6.698

6.  Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer.

Authors:  Antonia Rotolo; Matthew J Atherton; Brian T Kasper; Kumudhini P Haran; Nicola J Mason
Journal:  STAR Protoc       Date:  2021-10-22

7.  Disruption of chromosome 11 in canine fibrosarcomas highlights an unusual variability of CDKN2B in dogs.

Authors:  Jesús Aguirre-Hernández; Bruce S Milne; Chris Queen; Patricia C M O'Brien; Tess Hoather; Sean Haugland; Malcolm A Ferguson-Smith; Jane M Dobson; David R Sargan
Journal:  BMC Vet Res       Date:  2009-07-31       Impact factor: 2.741

8.  Serum-Free Suspension Culture of MDCK Cells for Production of Influenza H1N1 Vaccines.

Authors:  Ding Huang; Wen-Juan Peng; Qian Ye; Xu-Ping Liu; Liang Zhao; Li Fan; Kang Xia-Hou; Han-Jing Jia; Jian Luo; Lin-Ting Zhou; Bei-Bei Li; Shi-Lei Wang; Wen-Ting Xu; Ze Chen; Wen-Song Tan
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

9.  Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment.

Authors:  Takuya Mizuno; Yukinari Kato; Mika K Kaneko; Yusuke Sakai; Toshinori Shiga; Masahiro Kato; Toshihiro Tsukui; Hirofumi Takemoto; Akio Tokimasa; Kenji Baba; Yuki Nemoto; Osamu Sakai; Masaya Igase
Journal:  Sci Rep       Date:  2020-07-10       Impact factor: 4.379

10.  Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy.

Authors:  Charlotte M Mousset; Willemijn Hobo; Yun Ji; Hanny Fredrix; Valeria De Giorgi; Robert D Allison; Michel G D Kester; J H Frederik Falkenburg; Nicolaas P M Schaap; Joop H Jansen; Luca Gattinoni; Harry Dolstra; Anniek B van der Waart
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.